CERT 📈 Certara - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US15687V1098
CERT: Software, Biosimulation, Modeling, Simulation, Analysis, Automation
Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey. Web URL: https://www.certara.com
Additional Sources for CERT Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CERT Stock Overview
Market Cap in USD | 1,814m |
Sector | Healthcare |
Industry | Health Information Services |
GiC Sub-Industry | Health Care Technology |
IPO / Inception | 2020-12-11 |
CERT Stock Ratings
Growth 5y | -90.3% |
Fundamental | -9.13% |
Dividend | - |
Rel. Strength Industry | -790 |
Analysts | 3.73/5 |
Fair Price Momentum | 7.61 USD |
Fair Price DCF | 7.36 USD |
CERT Dividends
No Dividends PaidCERT Growth Ratios
Growth Correlation 3m | -5.4% |
Growth Correlation 12m | -86% |
Growth Correlation 5y | -84.1% |
CAGR 5y | -26.97% |
CAGR/Mean DD 5y | -0.52 |
Sharpe Ratio 12m | -0.99 |
Alpha | -74.19 |
Beta | 1.40 |
Volatility | 55.38% |
Current Volume | 3240.1k |
Average Volume 20d | 1504.4k |
What is the price of CERT stocks?
As of December 22, 2024, the stock is trading at USD 10.71 with a total of 3,240,121 shares traded.
Over the past week, the price has changed by -6.63%, over one month by +12.15%, over three months by -1.74% and over the past year by -35.48%.
As of December 22, 2024, the stock is trading at USD 10.71 with a total of 3,240,121 shares traded.
Over the past week, the price has changed by -6.63%, over one month by +12.15%, over three months by -1.74% and over the past year by -35.48%.
Is Certara a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Certara is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -9.13 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CERT as of December 2024 is 7.61. This means that CERT is currently overvalued and has a potential downside of -28.94%.
Neither. Based on ValueRay Fundamental Analyses, Certara is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -9.13 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CERT as of December 2024 is 7.61. This means that CERT is currently overvalued and has a potential downside of -28.94%.
Is CERT a buy, sell or hold?
Certara has received a consensus analysts rating of 3.73. Therefor, it is recommend to hold CERT.
Certara has received a consensus analysts rating of 3.73. Therefor, it is recommend to hold CERT.
- Strong Buy: 4
- Buy: 0
- Hold: 7
- Sell: 0
- Strong Sell: 0
What are the forecast for CERT stock price target?
According to ValueRays Forecast Model, CERT Certara will be worth about 8.5 in December 2025. The stock is currently trading at 10.71. This means that the stock has a potential downside of -20.73%.
According to ValueRays Forecast Model, CERT Certara will be worth about 8.5 in December 2025. The stock is currently trading at 10.71. This means that the stock has a potential downside of -20.73%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 14.3 | 33.3% |
Analysts Target Price | 18.6 | 73.4% |
ValueRay Target Price | 8.5 | -20.7% |